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Abstract 
This paper demonstrates how federal clinicians are collaborating with correctional health care providers 
in a unique continuing education initiative regarding HIV-medications and drug-drug interactions. Three 
clinical cases are presented to illustrate the potential dangers associated with concomitant use of ritonavir 
(a frequently prescribed antiretroviral agent) and illicit drugs. Such clinical cases are regularly presented 
in an exemplar program that draws clinicians together to share current medical information and notes 
“from the field” regarding problems that correctional health care providers and administrators are likely to 
face.  Collaboration between federal clinicians, correctional and community health officials has resulted 
in a unique forum for disseminating medical information, and represents a prototypical method for broad-
based health education. 
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The Challenges of Correctional Health Care 
The National Commission on Correctional 
Health Care (NCCHC) has provided estimates 
for the numbers of inmates released with 
communicable diseases and the percentages 
relative to the United States population with 
those infections.  Data from 1996 revealed that 
at least 1.3 million inmates released from 
correctional facilities in that year were infected 
with hepatitis C virus (HCV) (NCCHC, 2002) 
and these former inmates represented 29 percent 
of all U.S. cases of HCV infection.  Hepatitis B 
virus (HBV) infection, on the other hand, was 
found in 155,000 released inmates, accounting 
for 15.5 percent of all U.S. cases.  Significant 
fractions of HIV infection (98,000; 13 percent) 
and AIDS cases (39,000; 17 percent) were also 
reported among persons released from jails and 
prisons. It has been estimated that approximately 
one fourth of all HIV-infected persons in the 
U.S. pass through the corrections system each 
year (Laurence, 2005; NCCHC, 2002). 
 
Since the clinical management of HIV disease 
and hepatitis is constantly evolving, correctional 
health care providers and health services 
administrators must have access to continuing 
medical education.  This paper examines a pilot 
continuing-education-project in Washington, 
D.C., that involves collaboration between 
federal clinicians, correctional providers, and 
health services administrators. The Correctional 
Health Care Subcommittee is composed of 
representatives from correctional facilities in 
Virginia, Maryland, and the District of 
Columbia. Dr. Abe Macher, who serves as a 
volunteer clinical consultant to the Sub-
committee, has recruited representatives from 
the Federal Bureau of Prisons, the U.S. Marshals 
Service, the Veterans Administration, the Office 
of the Federal Public Defender for the District of 
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Columbia, the Centers for Disease Control and 
Prevention, local and state departments of 
health, community-based clinics, and hospice 
organizations (see Table 1) to participate in 
monthly multidisciplinary meetings where 
clinical cases are presented and discussed.  
State-of-the-art treatment updates regarding 
HIV/AIDS, hepatitis, bioterrorism, methicillin-
resistant Staphylococcus aureus, tuberculosis 
and other infectious disease issues are presented 
at each meeting. 
 
 
 
 
Table 1 
Participants of the Metropolitan Washington Council of Governments’ 
Correctional Health Care Subcommittee Meetings 
 
City, County, and Regional Detention Centers 
State Departments of Corrections 
Federal Bureau of Prisons 
U.S. Marshals Service 
Office of the Federal Public Defender for the District of Columbia 
Health Resources and Services Administration, U.S. Public Health Service 
Centers for Disease Control and Prevention, U.S. Public Health Service 
Veterans Administration 
County and State Departments of Health 
Community-Based HIV Clinics (e.g., La Clinica del Pueblo; Whitman Walker) 
AIDS Drug Assistance Programs 
Hospice of the Chesapeake 
University and Community Hospitals 
American Correctional Association 
American Jail Association 
Public Safety Division, Council of Governments 
 
 
 
 
A major concern of the Subcommittee is the 
proper use of FDA-approved HIV-medications 
and their potential toxicities and drug-drug 
interactions. An emerging dilemma within the 
metropolitan Washington, D.C. area is the 
interaction between prescribed HIV-medications 
(e.g., ritonavir) and illicit drugs such as 
hallucinogenic amphetamine derivatives (e.g., 
Methamphetamine; Ecstasy). Since a 
considerable number of HIV-infected inmates 
and former inmates are polysubstance abusers, 
they are at considerable risk for drug-drug 
interactions between their prescribed HIV-
medications and illicit drugs.  In addition to 
educating the correctional providers and 
administrators, physicians educate inmates, 
focusing on post-release continuity of 
antiretroviral treatment and avoidance of illicit 
(interactive) drugs. 
 
Inter-Agency Collaborative Education: An 
Exemplar Program 
In 1998, the Congressional Black Caucus 
declared HIV/AIDS a medical emergency 
among indigent African-Americans, and 
highlighted the problem within our nation’s 
correctional facilities. The Caucus requested 
volunteers from the United States Public Health 
Service (USPHS) to provide clinical assistance.  
Dr. Macher, a USPHS physician, volunteered to 
create a regional correctional HIV program, and 
volunteered to serve as clinical consultant to the 
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Metropolitan Washington Council of 
Governments’ Correctional Health Care 
Subcommittee. He recruited clinicians from the 
region to join the Subcommittee.  Since 1998, 
the Subcommittee has been meeting on a 
monthly basis to address HIV/AIDS as well as 
other infectious disease issues, including 
bioterrorism. Dr. Macher presents patients’ 
clinical cases at each meeting of the 
Subcommittee. The following three clinical 
cases focus on drug-drug interactions between 
the prescribed antiretroviral agent ritonavir and 
illicit drugs. 
 
Clinical Case One: Ecstasy and Ritonavir 
The patient, a man with HIV-infection with a 
history of alcohol abuse and illicit use of 
“Ecstasy”(3,4 methylenedioxymethamphetamine 
or street names of MDMA; XTC; X; M; E; 
Clarity; Adam; Essence; Ecky; Bicky; Yaoto-
Wang) was prescribed an antiretroviral treatment 
regimen that included the protease inhibitor 
ritonavir.  Two weeks after starting treatment 
with ritonavir, he went to a club and took three 
MDMA (Ecstasy) tablets.  In the past (prior to 
being prescribed ritonavir) he had taken MDMA 
on several occasions without untoward effects. 
 
Four hours after his arrival at the club, a nurse 
noted that he was hypertonic, sweating 
profusely, tachypneic (approximately 45 breaths 
per minute), tachycardic (in excess of 140 beats 
per minute), and cyanosed.  He was able to talk 
in full sentences and gave a history of having 
taken two MDMA tablets with little effect, so he 
took a further half-tablet (estimated total dose 
180 mg MDMA, calculated from the MDMA 
content of the remaining half tablet), after which 
he began to “feel shaky.”  Within 25 minutes of 
the first assessment he had an apparent tonic-
clonic convulsion, but was able to respond to 
questions.  He became increasingly tachypneic, 
and his carotid pulse rate was approximately 200 
per minute.  A few minutes later he vomited and 
had a cardiopulmonary arrest. Attempts at 
resuscitation were unsuccessful. 
 
Postmortem toxicology revealed MDMA in his 
blood at a concentration of 4.56 mg/L (ten times 
the anticipated concentration). The protease 
inhibitor ritonavir is an inhibitor of cytochrome 
P450 2D6 (CYP2D6), an isoenzyme responsible 
for demethylenation – the principal pathway by 
which MDMA is metabolized.  Thus, ingestion 
of MDMA in recreational amounts by a person 
taking ritonavir can lead to toxic effects due to 
high plasma concentrations of MDMA.  This 
patient’s death was consistent with a severe 
serotoninergic reaction to MDMA. Adverse 
effects of MDMA ingestion result from 
sympathetic overload and include tachycardia, 
diaphoresis, tremor, hypertension, arrhythmias, 
parkinsonism, and urinary retention. The most 
serious potential outcome of MDMA ingestion 
is hyperthermia and the associated “serotonin 
syndrome” manifested by grossly elevated core 
body temperature, rigidity, myoclonus, and 
autonomic instability; patients may develop 
rhabdomyolysis and acute renal failure, hepatic 
failure, adult respiratory distress syndrome, and 
coagulopathy (Gahlinger 2004). 
 
Clinical Case Two: Methamphetamine, Amyl 
Nitrate, and Ritonavir 
A man with HIV-infection and a history of 
recreational drug use was prescribed an 
antiretroviral treatment regimen that included 
ritonavir.  Four months later, he was witnessed 
injecting himself twice with methamphetamine 
(Meth, Crystal) as well as sniffing amyl nitrate. 
His friends left him at approximately 3:00 a.m., 
apparently asleep, lying on his stomach on the 
floor.  The next day he was found dead in the 
same position in which he had been left. 
 
Postmortem toxicology detected meth-
amphetamine at a level of 0.5 mg/L in his blood 
(Hales, Roth, & Smith, 2000). This patient had 
also been abusing amyl nitrate.  Amyl nitrate is 
metabolized to nitric oxide which inhibits 
cytochrome P450, and ritonavir inhibits 
CYP2D6 which has a major role in 
methamphetamine metabolism. These drug-drug 
interactions probably led to the high plasma 
concentrations of methamphetamine.   
 
Clinical Case Three: Ecstasy, GHB, and 
Ritonavir 
A man with HIV-infection began taking an 
antiretroviral treatment regimen that included 
ritonavir.  Harrington, Woodward, Hooton, and 
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Horn (1999, p. 2221) reported that five days 
later the following occurred: 
 
Twenty minutes after ingesting a half 
teaspoon of “Liquid Ecstasy” (gamma-
hydroxybutyrate, or GHB), the man became 
unresponsive and exhibited a brief episode 
of repetitive, clonic contractions of both legs 
and then the left side of his body. 
Emergency medical personnel found him 
responsive only to painful stimuli, with 
shallow respirations and a heart rate of only 
40 per minute. He was endotracheally 
intubated and transferred to a local hospital.  
A toxicology screen was positive for 
methamphetamine and MDMA.  During the 
next three hours, his vital signs normalized 
and he woke up and extubated himself.  
Upon questioning, he admitted to ingesting 
two MDMA tablets approximately 29 hours 
prior to admission.  Six hours prior to 
admission, he ingested one half teaspoon of 
GHB, and a similar dose of GHB 
immediately before becoming unconscious.  
He stated that he took the GHB to counter 
the agitating effects of MDMA, which had 
persisted for more than one day after 
ingestion.  The patient noted that prior to his 
use of ritonavir, he had taken a similar 
quantity of GHB as a sleep aide on many 
occasions and he had never experienced any 
adverse reactions.  He also noted that his 
friends had consumed similar amounts of the 
same preparation of GHB every two to three 
hours without any adverse effects. 
 
The patient maintained that the duration 
(>29 hours) of the stimulatory effect of the 
MDMA he ingested was much longer than 
when he had taken similar doses of MDMA 
in the past (prior to his antiretroviral 
treatment with ritonavir).  He explained that 
the sustained effects of MDMA are what 
prompted him to take GHB, given its 
sedating qualities. He proceeded to 
experience clinical features typical of GHB 
poisoning with a rapid onset of loss of 
consciousness, seizure-like activity, and 
respiratory depression. Ritonavir probably 
inhibited the metabolism of both MDMA 
and GHB in this patient. 
Discussion 
These three clinical cases underscore the hazards 
of mixing illicit drugs with prescribed HIV-
medications. Given the variations in drug 
absorption and metabolism that exist between 
individuals, it is impossible to accurately predict 
the effect of drug combinations in any one 
person. This is particularly important with 
regard to the use of illicit drugs, which are often 
taken by groups of people.  Individuals within 
the group may be falsely reassured by others that 
such drug combinations are safe. 
 
A prudent approach for HIV providers would be 
to caution their patients that the known and 
potential drug interactions between illicit 
substances and HIV-medications are complex 
and unpredictable. Co-administration of HIV-
medications with illicit substances should be 
strongly discouraged. Consequently, correctional 
health care providers should utilize each clinical 
visit with their inmate-patients as opportunities 
for ongoing continuing education and 
preparation for post-release continuity-of-care. 
 
Conclusions 
Each year, some 630,000 persons are released 
from state and federal prisons (Office of Justice 
Programs, 2005). Moreover, another 13.6 
million persons are arrested, and are admitted 
and discharged from county jails and juvenile 
detention centers (Federal Bureau of 
Investigation, 2004).  Rates of illicit drug use in 
this population are very high (see James, 2004), 
and these detainees and inmates also engage in 
other risky behaviors.   
 
Following admission to a correctional facility, 
inmates represent a “captive audience” and 
interventions that attempt to reduce their risky 
behaviors should be undertaken. Correctional 
officials and clinicians must first, however, have 
a clear understanding of the risks that their 
populations are likely to engage. The 
correctional health care initiative in Washington, 
DC, is an exemplar program that unites local, 
state, and federal agencies and organizations and 
promotes ongoing education, communication, 
cooperation, collaboration, and continuity-of-
care.  We recommend that correctional facilities 
unite in their respective regions by accessing 
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their local Councils of Governments (or 
equivalent organizations) and pooling their 
area’s clinical and educational resources 
(Macher et al., 2002). 
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